MONDAY, Oct. 16, 2017 -- Surgery is the main treatment for melanoma -- a dangerous form of skin cancer -- but a patient's insurance could affect whether or not that cancer is quickly removed, new research suggests.
After reviewing thousands of melanoma cases, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center reported that patients with Medicaid were more likely to face delays in scheduling their surgery than those with private insurance.
WEDNESDAY, Oct. 25, 2017 -- Nearly 40 percent of indoor tanning facilities ignore state laws that curb teen tanning, a new survey finds.
To protect teens, most states have laws that prevent or create obstacles to using tanning salons, but nearly 2 million high school kids still get indoor tans, said the researchers who conducted the survey.
FRIDAY, Oct. 27, 2017 -- Children and adults with eczema shouldn't suffer in silence because new, improved treatments can do more to help ease the uncomfortable, itchy rash associated with the skin condition.
Many adults diagnosed with eczema (atopic dermatitis) actually had the condition since they were children but were never diagnosed, explained Dr. Luz Fonacier. She is an allergist in Mineola, N.Y., and an American College of Allergy, Asthma and Immunology (ACAAI) board member.
TUESDAY, Oct. 10, 2017 -- How to keep from developing skin cancer should be something all doctors discuss with the parents of their young, fair-skinned patients, suggests the U.S. Preventive Services Task Force.
Those conversations should begin much earlier than previously recommended -- starting when a child is just 6 months old, according to new recommendations from the task force.
WEDNESDAY, Sept. 6, 2017 -- Many skin moisturizers that claim to be fragrance-free or hypoallergenic are not, and may aggravate skin disorders such as psoriasis and eczema, a new study says.
Northwestern University researchers examined the top 100 best-selling, whole-body moisturizers sold at Amazon, Target and Walmart for affordability and content. They found that 83 percent of so-called hypoallergenic products had a potentially allergenic chemical.
MONDAY, Sept. 11, 2017 -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors.
The international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.